Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers in CRC, and is recommended in the guidelines of the National Comprehensive Cancer Network (NCCN) for prognostic assessment and disease monitoring [4,5,6,7,8,9]. The gene discussed is CEACAM5; the disease is neoplasm.